Ascendis Pharma A (ASND) Consolidated Net Income (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Consolidated Net Income data on file, last reported at $736.8 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 857.21% year-over-year to $736.8 million; the trailing twelve-month figure through Mar 2026 stood at $615.6 million (up 270.95% YoY), and the FY2025 full-year result was -$293.7 million, up 28.22% from the prior year.
• Consolidated Net Income rose to $736.8 million in Q1 2026, from -$23.1 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $736.8 million in Q1 2026 to a low of -$200.7 million in Q4 2022.
• A 5-year average of -$58.0 million and a median of -$106.7 million in 2024 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income slumped 85.25% in 2022 and soared 857.21% in 2026, its largest moves.
• Tracing ASND's Consolidated Net Income over 5 years: stood at -$200.7 million in 2022, then soared by 59.64% to -$81.0 million in 2023, then surged by 52.12% to -$38.8 million in 2024, then surged by 40.44% to -$23.1 million in 2025, then surged by 3289.05% to $736.8 million in 2026.
• Business Quant data shows ASND's Consolidated Net Income at $736.8 million in Q1 2026, -$23.1 million in Q4 2025, and -$62.8 million in Q3 2025.